There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Novo Nordisk (NVO – Research Report) and Vincerx Pharma Inc (VINC – Research Report) with bullish sentiments.
Novo Nordisk (NVO)
In a report released today, Richard Vosser from J.P. Morgan upgraded Novo Nordisk to Buy. The company’s shares closed last Monday at $112.15.
According to TipRanks.com, Vosser is a 5-star analyst with an average return of
Novo Nordisk has an analyst consensus of Strong Buy, with a price target consensus of $130.00, implying a 15.4% upside from current levels. In a report issued on May 31, Guggenheim also upgraded the stock to Buy.
Vincerx Pharma Inc (VINC)
In a report released today, Jonathan Chang from SVB Securities maintained a Buy rating on Vincerx Pharma Inc, with a price target of $6.00. The company’s shares closed last Monday at $1.83, close to its 52-week low of $1.40.
According to TipRanks.com, Chang is ranked 0 out of 5 stars with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Vincerx Pharma Inc with a $16.00 average price target, which is a 784.0% upside from current levels. In a report released today, B.Riley Financial also maintained a Buy rating on the stock with a $6.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on NVO: